卵巢癌患者血清及腹水白细胞介素6测定的临床意义  

CLINICAL SIGNIFICANCE OF THE DETERMINATIONS OF INTERLEUKIN 6 IN SERUM AND ASCITES OF THE PATIENTS WITH OVARIAN CANCER

作　　者：潘继存[1] 徐新 江森[1] 刘伟国[2,3,4] 

机构地区：[1]山东医科大学附属医院 [2]白求恩医科大学第一附属医院 [3]泰山医学院附属医院妇产科 [4]泰山医学院免疫室

出　　处：《中国免疫学杂志》1997年第4期242-244,共3页Chinese Journal of Immunology

摘　　要：选择未接受治疗的原发性卵巢上皮癌３３例、良性卵巢上皮肿瘤１２例及正常妇女行输卵管吻合术者１０例作为研究对象，采用ＩＬ－６依赖性细胞株ＭＨ６０－ＢＳＦ２增殖反应ＭＴＴ法测定血清及腹水（或腹腔液）中ＩＬ－６水平。结果表明，卵巢癌患者血清及腹水中ＩＬ－６水平明显高于良性卵巢上皮肿瘤及正常对照组，临床晚期（Ⅲ－Ⅳ）者ＩＬ－６水平明显高于临床早期（Ⅰ－Ⅱ）者，但良性组与正常对照组之间无差异，提示ＩＬ－６水平的检测有助于卵巢癌的早期诊断、鉴别诊断及判断治疗效应，卵巢癌患者腹水中高水平的ＩＬ－６与卵巢癌细胞的增殖与转移有关。33 patients with previously untreated,primary epithelial ovarian cancer were studied by MH60 BSF2 cell which depended on IL 6 proliferative action with MTT method to determine IL 6 levels of serum and ascites(or peritoneal liquid).Collected some samples as control.The results showed that IL 6 levels of serum and ascites in patients with ovarian cancer elevated frequently and correlated with advanced stages of ovarian cancer(Ⅲ Ⅳ),no significant difference between the healthy women and the patients with benign ovarian epithelial tumor.The results suggested that determinations of IL 6 had helped to define and diagnose the disease earlier,observe the effect of treatment.The elevated level of IL 6 in ascites of patients with ovarian cancer correlated with proliferation and metastasis of ovarian cancer cells.

关 键 词：细胞因子 卵巢肿瘤 血清 腹水 白细胞介素6 

分 类 号：R737.310.3[医药卫生—肿瘤]